Neil Blumberg: Clinical Harm Associated With Infusion of ABO Incompatible Antibody and Antigen
Neil Blumberg, Transfusion Medicine Specialist and Platelet Researcher (Former Professor and Director, URMC), shared on LinkedIn:
“Some ideas become dogma without any strong data to support them. Examples include the equivalent safety of universal donor group O red cells and group AB plasma to ABO identical transfusions. Data have now accumulated to show that these assumptions are largely incorrect.
Our group reviewed the data demonstrating that infusion of modest amounts of ABO incompatible cellular and soluble antigen, and ABO incompatible plasma are associated with clinical harm, including increased mortality.
Tong N, Masel D, Nguyen PL, Asante A, Refaai M, Heal JM, Blumberg N.
The case against infusing ABO incompatible antibody and antigen from all blood components.
Transfus Apher Sci. 2026 Jan 31;65(2):104402. doi: 10.1016/j.transci.2026.104402. Epub ahead of print. PMID: 41633302.
Abstract
The transfusion of ABO compatible but not ABO identical red blood cells and plasma and the transfusion of platelets and cryoprecipitate without concern for ABO in any manner, are practices that have been accepted as safe for patients.
While these practices make managing blood component inventories easier by reducing component outdating, they do lead to the development of immune complexes, donor antibody induced hemolysis, and potentially endothelial cell and platelet injury.
A growing body of evidence has shown that these practices are associated, likely causally, with negative consequences for patients including increased mortality.
The adoption of a policy of providing only ABO identical blood components when practical, and avoiding infusion of ABO incompatible antibody, cellular and soluble antigen should thus become the optimal standard of care for patients.
For those without access to the full article, request a .pdf from [email protected].”
Find more posts featuring Neil Blumberg on Hemostasis Today.
-
Feb 8, 2026, 16:20Paul Kim: Exciting Week of Excellent Science at the 2026 GRC on Plasminogen Activation and Extracellular Proteases
-
Feb 8, 2026, 16:12Ney Carter Borges: How RSV Hospitalization is Linked to Sharp Rise in Heart Attack and Stroke Risk
-
Feb 8, 2026, 16:07New BSH–UKHCDO Guideline on Acquired Coagulation Factor Inhibitors
-
Feb 8, 2026, 16:04Mahesan Subramaniam: Pomegranate Juice and Heart Health
-
Feb 8, 2026, 16:02Mark Young: The More Science Listens, the More It Hears – Matter, Frequency, and Resonance
-
Feb 8, 2026, 15:53Julieta Rosales: ISC 2026 Data on Intravenous Thrombolysis in the Late Window
-
Feb 8, 2026, 15:51Alison L. Bailey: Wearing Red to Raise Awareness of Women’s N1 Killer on National Go Red Day
-
Feb 8, 2026, 15:44Jan Sloves։ Pedal Venous Maturation Predicts Limb Salvage in No‑Option CLTI
-
Feb 8, 2026, 15:26Abdulrahman Katib։ Anticoagulate or Observe? A Practical Approach to Isolated Distal DVT